Literature DB >> 10896202

Analysis of the p300/CBP-Associated Factor (PCAF) gene in astrocytic tumors.

H Nishimori1, R Nishikawa, T Fujimaki, T Nakagomi, M Matsutani, H J Huang, W K Cavenee.   

Abstract

The PCAF gene encodes the p300/CBP-Associated Factor (PCAF), a histone acetyltransferase, which regulates p53 by acetylation of Lys320 in the C-terminal portion of p53. While the p53 gene is one of the most frequently mutated tumor suppressor genes in human tumors, such mutations occur in only 30% of astrocytic tumors. Since PCAF can regulate p53 activity, abrogation of PCAF function by PCAF gene mutation could be an alternate mechanism to inactivate the p53 pathway in tumors lacking p53 mutations. To test this hypothesis, we determined the nucleotide sequence of the entire PCAF coding region in 37 astrocytic tumors (17 glioblastomas, 10 anaplastic astrocytomas, 7 low-grade astrocytomas, and 3 pilocytic astrocytomas). We detected two single-nucleotide alterations that represented non-deleterious polymorphisms (GAG > GAA Glu103Glu, AAT > AGT Asn386Ser) but no obvious functional mutations. Moreover, the frequency of the Asn386Ser allele that contained Ser386 in glioma patients was not statistically different from its frequency in individuals without disease, and no significant association was observed between the PCAF polymorphisms and the presence or absence of p53 mutations in the tumors. We conclude that the PCAF gene is not mutated during the development of the astrocytic tumors studied here.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10896202     DOI: 10.1023/a:1006404110073

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  15 in total

1.  p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage.

Authors:  L Liu; D M Scolnick; R C Trievel; H B Zhang; R Marmorstein; T D Halazonetis; S L Berger
Journal:  Mol Cell Biol       Date:  1999-02       Impact factor: 4.272

2.  DNA damage activates p53 through a phosphorylation-acetylation cascade.

Authors:  K Sakaguchi; J E Herrera; S Saito; T Miki; M Bustin; A Vassilev; C W Anderson; E Appella
Journal:  Genes Dev       Date:  1998-09-15       Impact factor: 11.361

3.  Histone acetyltransferase activity and interaction with ADA2 are critical for GCN5 function in vivo.

Authors:  R Candau; J X Zhou; C D Allis; S L Berger
Journal:  EMBO J       Date:  1997-02-03       Impact factor: 11.598

4.  Tetrahymena histone acetyltransferase A: a homolog to yeast Gcn5p linking histone acetylation to gene activation.

Authors:  J E Brownell; J Zhou; T Ranalli; R Kobayashi; D G Edmondson; S Y Roth; C D Allis
Journal:  Cell       Date:  1996-03-22       Impact factor: 41.582

Review 5.  A molecular genetic model of astrocytoma histopathology.

Authors:  D N Louis
Journal:  Brain Pathol       Date:  1997-04       Impact factor: 6.508

6.  Comparative study of p53 gene and protein alterations in human astrocytic tumors.

Authors:  D N Louis; A von Deimling; R Y Chung; M P Rubio; J M Whaley; R H Eibl; H Ohgaki; O D Wiestler; A D Thor; B R Seizinger
Journal:  J Neuropathol Exp Neurol       Date:  1993-01       Impact factor: 3.685

7.  CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated.

Authors:  K Ueki; Y Ono; J W Henson; J T Efird; A von Deimling; D N Louis
Journal:  Cancer Res       Date:  1996-01-01       Impact factor: 12.701

8.  p53 mutation and loss of heterozygosity on chromosomes 17 and 10 during human astrocytoma progression.

Authors:  D Fults; D Brockmeyer; M W Tullous; C A Pedone; R M Cawthon
Journal:  Cancer Res       Date:  1992-02-01       Impact factor: 12.701

9.  Lack of p16INK4 or retinoblastoma protein (pRb), or amplification-associated overexpression of cdk4 is observed in distinct subsets of malignant glial tumors and cell lines.

Authors:  J He; J J Olson; C D James
Journal:  Cancer Res       Date:  1995-11-01       Impact factor: 12.701

10.  CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas.

Authors:  E E Schmidt; K Ichimura; G Reifenberger; V P Collins
Journal:  Cancer Res       Date:  1994-12-15       Impact factor: 12.701

View more
  1 in total

1.  Mutation analysis of CBP and PCAF reveals rare inactivating mutations in cancer cell lines but not in primary tumours.

Authors:  H Ozdağ; S J Batley; A Försti; N G Iyer; Y Daigo; J Boutell; M J Arends; B A J Ponder; T Kouzarides; C Caldas
Journal:  Br J Cancer       Date:  2002-11-04       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.